ASP Isotopes Inc. filed a Form 8-K to disclose that ENDRA Life Sciences Inc. submitted a Registration Statement on Form S-4 with the SEC regarding their proposed merger transaction. The Merger Agreement, originally signed on June 25, 2026, involves ASP Isotopes' subsidiary Noble Africa merging into Merger Sub, a subsidiary of ENDRA, resulting in Noble Africa surviving as a wholly-owned subsidiary of ENDRA. This filing incorporates by reference information from the Form S-4, which includes details about Renergen Limited, another ASP Isotopes subsidiary involved in the strategic combination. The transaction is subject to customary closing conditions and regulatory approvals. ASP Isotopes Inc. operates in the nuclear medicine and isotopes industry.
